An accomplished pharmaceutical executive based in Teaneck, New Jersey, John Klein is the chairman of Cambridge Therapeutics. In his capacity with Cambridge Therapeutics, he oversees the development of novel drug delivery systems and combination drug therapies. John Klein also keeps up with industry news related to areas such as novel drug delivery systems.
A new and exciting frontier in the field of pharmaceuticals, novel drug delivery systems aim to improve therapeutic efficacy and increase patients’ compliance with their prescribed regimens. New advancements in the field are happening at Virginia Tech, where faculty researchers have developed a novel drug delivery system with the potential to enhance cancer treatment options.
Current treatments that involve injecting nanoparticle drugs into patients have limited effectiveness because few of those nanoparticles reach the cancer site. On the other hand, through the new Nanoscale Bacteria-Enabled Autonomous Drug Delivery System (NanoBEADS), anti-cancer nanoparticle drugs are chemically attached to attenuated bacteria cells, which boosts the effectiveness of the treatment by allowing more of the therapeutic agents to reach the cancer site.
No comments:
Post a Comment